FLT3 and acute myeloid leukemia: Adult studies have shown a prevalence of 25–30% for the FLT3-ITD+ in AML patients who have no cytogenetic abnormalities (Schnittger et al., 2002; Patnaik 2018; Griffith et al., 2004) and ~7% for FLT3-KTD point mutation of the activation loop domain (Bacher et al., 2008; Yamamoto et al., 2001; Kim 2010).